Design, Synthesis, and Pharmacological Evaluation of cGAS/HDAC Dual Inhibitors for Treatment of Autoimmune Diseases
Journal of Medicinal Chemistry · 25.06.2026 · 69 (12) · 14601-14626
DOI: 10.1021/acs.jmedchem.6c00583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.06.2026. Verfasst von Zihua Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shang…. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Drug Design, Nucleotidyltransferases, Autoimmune Diseases. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai QiYuan Innovation Foundation, National Innovation of Science and Technology-2030.
Abstract (Originalsprache)
cGAS overactivation is linked to various inflammatory and autoimmune diseases. Recent studies identify HDACs as critical regulators of cGAS, suggesting that dual cGAS/HDAC inhibition could be a novel therapeutic strategy. Herein, we report the identification of an HDAC/cGAS dual inhibitor, 31h, containing a hydroxamic acid moiety. This compound exhibited potent inhibitory activity against human and mouse cGAS (IC 50: 0.17 and 1.80 μM, respectively) and moderate activity against HDAC3 and HDAC6 (IC 50: 1.2 and 0.4 μM, respectively). Mechanistically, 31h directly suppresses cGAS activity and increases its acetylation levels via HDAC3 inhibition. This dual–action profile resulted in robust therapeutic efficacy in murine models of inflammatory bowel disease and Aicardi–Goutières syndrome. Collectively, 31h represents the first cGAS/HDAC dual inhibitor, offering a promising lead for further investigation into cGAS-dependent disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
- State Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, 800 Dongchuan Road, Minhang District, Shanghai 200240, China.
- Zhejiang Pharmaceutical University, Ningbo 315100, China.
- State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- School of Medicine, Anhui University of Science and Technology, Huainan 232001, China.
ORCID-Profile: Chunyong Ding, Ao Zhang
Förderung
- National Natural Science Foundation of China
- Shanghai QiYuan Innovation Foundation
- National Innovation of Science and Technology-2030
- Innovative Drug Research and Development National Science and Technology Major Project
Zitieren
APA
Zhou, Z., Chen, M., Lei, S., Wang, M., Ding, C., Song, Z., Tang, W., & Zhang, A. (2026). Design, Synthesis, and Pharmacological Evaluation of cGAS/HDAC Dual Inhibitors for Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry, 69(12), 14601-14626. https://doi.org/10.1021/acs.jmedchem.6c00583
Vancouver
Zhou Z, Chen M, Lei S, Wang M, Ding C, Song Z, et al. Design, Synthesis, and Pharmacological Evaluation of cGAS/HDAC Dual Inhibitors for Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry. 2026;69(12):14601-14626. doi:10.1021/acs.jmedchem.6c00583
BibTeX
@article{Zhou2026,
author = {Zhou, Zihua and Chen, Mingjie and Lei, Shuyue and Wang, Meng and Ding, Chunyong and Song, Zilan and Tang, Wei and Zhang, Ao},
title = {Design, Synthesis, and Pharmacological Evaluation of cGAS/HDAC Dual Inhibitors for Treatment of Autoimmune Diseases},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {12},
pages = {14601--14626},
doi = {10.1021/acs.jmedchem.6c00583}
}
EUVIMED